Online inquiry

IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1424MR)

This product GTTS-WQ1424MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MUC16 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_024690.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 94025
UniProt ID Q8WXI7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1424MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8044MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ5551MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ5438MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDA 1
GTTS-WQ15555MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ1021MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-399
GTTS-WQ2731MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG-139
GTTS-WQ11728MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-0646
GTTS-WQ945MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-321
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW